Linearis Labs Inc., a company intersecting AI and biomarker analysis, opened its new laboratory facilities at a site formerly occupied by Medicago Inc. Linearis acquired over 650 scientific instruments and hired some of Medicago’s specialized personnel in mass spectrometry, quality assurance, and laboratory management.
 
The combination of AI and high-throughput automated analysis of 1,400 metabolomic biomarkers enables Linearis to better identify numerous elements associated with metabolic diseases including cancer, diabetes, and antimicrobial resistance. This global approach aims to improve prevention, screening, treatment monitoring, and drug discovery. Linearis’ analytical services cater to biobanks, researchers, clinical research organizations, and biopharmaceutical companies.
 
“We are grateful for the support from Medicago during this transaction enabling the creation of this innovative and collaborative laboratory. The identification of disease signatures not only makes prevention accessible, but it also contributes to improving the prevention, screening, discovery of treatments, and acceleration of precision medicine,” said Alexandre Le Bouthillier, President and CEO of Linearis.
 
“We wish the laboratory instruments acquired by Linearis as a part of our wind-up process, contribute to the advancements in biotechnology and AI while bearing the fruits of a healthy future accessible to all,” said Toshifumi Tada, President and CEO of Medicago.